Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2022 Annual General Meeting | 25 Nov 2021 |
| Orion Group Interim Report 1–9/2021 | 20 Oct 2021 |
| Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) | 8 Oct 2021 |
| Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) | 8 Oct 2021 |